Sanofi: Targeted therapy drug for chronic obstructive pulmonary disease (COPD), Dabitou, approved in China
我放心你带套猛
发表于 2 小时前
119
0
0
On September 27th, Sanofi announced that Dapitumab Injection has been approved by the China National Medical Products Administration for use in adult patients with chronic obstructive pulmonary disease who have elevated blood eosinophils and poor control. This approval is based on the results of two milestone Phase III clinical trials, which showed that dabigatur (once every two weeks) significantly reduced acute exacerbations and improved lung function.
CandyLake.com 系信息发布平台，仅提供信息存储空间服务。
声明：该文观点仅代表作者本人，本文不代表CandyLake.com立场，且不构成建议，请谨慎对待。
声明：该文观点仅代表作者本人，本文不代表CandyLake.com立场，且不构成建议，请谨慎对待。
转播
猜你喜欢
- Starbucks needs to find partners as revenue in China declines year-on-year
- Pfizer's new hemophilia treatment drug Mataximab's application for market launch in China has been accepted
- General Motors China responds to rumors of layoffs and capacity cuts: all business in China is high-quality assets
- It is reported that Tesla plans to start producing a six seater version of the Model Y in China by the end of 2025
- The Class 1 new drug introduced by Anjin with over 1 billion US dollars has been approved for clinical use
- Mercedes Benz invests another 14 billion yuan to deepen its layout in China and enrich its "Made in China" product lineup with "Chinese speed"
- JD Allianz Equity Transfer Approved: Allianz Insurance Group to Transfer 53.33% Equity of the Company to Allianz China Holdings
- Tianjing Biotechnology grants Sanofi the rights to Yulelimab in China with a down payment of 250 million yuan
- Sanofi's targeted therapy drug for chronic obstructive pulmonary disease, Dabitou, has been approved in China
- The targeted therapy drug for chronic obstructive pulmonary disease, Dabitou, has been approved in China
-
大雪と網易が「複合」した後、大雪系傘下のゲームが次々と国服に復帰しつつあり、9月25日、魔獣世界に続き、大雪系ゲームの「現金牛」、カードゲーム「炉石伝説」が正式に国服に復帰した。午前7時26分、新京報貝殻 ...- vvsky
- 前天 17:14
- 支持
- 反对
- 回复
- 收藏
-
上証報中国証券網（何奎記者）は9月25日、国内頭部保険電子商取引サービスプラットフォームの慧択氏が米国株の開場前に発表した2024年第2四半期の未監査業績報告によると、上半期の慧択全プラットフォームによる総 ...- 18010063851
- 昨天 11:44
- 支持
- 反对
- 回复
- 收藏
-
百勝中国9月23日のニュースによると、百勝中国と保利発展ホールディングスはこのほど、広州保利発展広場で戦略協力協定に調印した。双方はそれぞれのビジネス分野での技術、管理、ブランドの優位性を十分に利用し、 ...- 寒郁轩良
- 前天 16:28
- 支持
- 反对
- 回复
- 收藏
-
【世界市場】1、納指は0.04%、ダウは0.70%、スタンダードは0.19%下落した。2、英偉達は2%超上昇し、美光科技の株価は10%超上昇した。3、ナスダック中国の金龍指数は2.80%、蔚来は5%近く下落した。4、国際原油価格は ...- 虚空一粒沙2017
- 昨天 21:42
- 支持
- 反对
- 回复
- 收藏
